Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD-003 in Chronic Renal Failure
NCT02378194Phase 2Completed
- Sponsor
- Hyundai Pharmaceutical Co., Ltd.
- Start
- Jan 2010
- Primary completion
- Mar 2013
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial of 5-hydroxy-1-methylhydantoin in chronic kidney disease (CKD) (3 arms), sponsored by Hyundai Pharmaceutical Co., Ltd. Primary endpoints: serum creatinine rate inverse number's change at 24 weeks and GFR measurements at 24 weeks. Started Jan 2010; status: completed.
02
Drugs
5-hydroxy-1-methylhydantoin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02378194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02378194.